Innate and adaptive immune response in fabry disease

JIMD Reports

Volumn 22, Issue , 2015, Pages 1-10

  Mauhin, Wladimir ^a,c   Lidove, Olivier ^b,c   Masat, Elisa ^c   Mingozzi, Federico ^c   Mariampillai, Kuberaka ^c   Ziza, Jean Marc ^b   Benveniste, Olivier ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^c Groupe Hospitalier Pitié Salpêtrière   (France)

Author keywords

Agalsidase; Enzyme replacement therapy; Fabry disease (OMIM 301500); Immune response; Lysosomal storage disease; TLR4

Indexed keywords

EID: 84949680395     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2014_371     Document Type: Chapter

References (95)

1. Aerts JM, Groener JE, Kuiper S et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105:2812–2817. doi:10.1073/pnas.0712309105
2. Anders H-J, Banas B, Schlöndorff D (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15:854–867
3. Balreira A, Macedo MF, Girão C et al (2008) Anomalies in conventional T and invariant natural killer T-cell populations in Fabry mice but not in Fabry patients. Br J Haematol 143:601–604. doi:10.1111/j.1365-2141.2008.07380.x
4. Banas MC, Banas B, Hudkins KL et al (2008) TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19:704–713. doi:10.1681/ASN.2007040395
5. Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
6. Banugaria SG, Prater SN, Patel TT et al (2013) Algorithm for the early diagnosis and treatment of patients with cross reactive immuno-immuno-logic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PLoS One 8(6):e67052 logic
7. Barbey F, Lidove O, Schwarting A (2008) Fabry nephropathy: 5 years of enzyme replacement therapy—a short review. NDT Plus 1 (1):11–19
8. Beck M (2006) Demographics of FOS – the Fabry outcome survey. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford
9. Bekri S (2006) Importance of glycosylation in enzyme replacement therapy. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Source Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford
10. Bénichou B, Goyal S, Sung C et al (2009) A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 96:4–12. doi:10.1016/j.ymgme.2008.10.004
11. Biancini GB, Vanzin CS, Rodrigues DB et al (2012) Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta 1822:226–232. doi:10.1016/j. bbadis.2011.11.001
12. Boyd RE, Lee G, Rybczynski P et al (2013) Pharmacological chaperones as therapeutics for lysosomal storage diseases. J Med Chem 56:2705–2725. doi:10.1021/jm301557k
13. Caielli S, Conforti-Andreoni C, Di Pietro C et al (2010) On/off TLR signaling decides proinflammatory or tolerogenic dendritic cell maturation upon CD1d-mediated interaction with invariant NKT cells. J Immunol 185:7317–7329. doi:10.4049/jimmu-nol.1000400
14. Chimenti C, Pieroni M, Morgante E et al (2004) Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110:1047–1053. doi:10.1161/01. CIR.0000139847.74101.03
15. Chuang Y-P, Wang C-H, Wang N-C et al (2012) Modulatory function of invariant natural killer T cells in systemic lupus erythematosus. Clin Dev Immunol 2012:478429. doi:10.1155/2012/478429
16. De Francesco PN, Mucci JM, Ceci R et al (2011) Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: Effect of globotriaosylceramide. Mol Genet Metab 104:319–324. doi:10.1016/j.ymgme.2011.06.007
17. De Francesco PN, Mucci JM, Ceci R et al (2013) Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab 109:93–99. doi:10.1016/j.ymgme.2013.02.003
18. De Vries JM, van der Beek NAME, Kroos MA et al (2010) High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101:338–345. doi:10.1016/j.ymgme.2010.08.009
19. Deegan PB (2012) Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis 35:227–243. doi:10.1007/s10545-011-9400-y
20. DeGraba T, Azhar S, Dignat-George F et al (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47:229–233
21. Dickson P, Peinovich M, McEntee M et al (2008) Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 118(8):2868–2876
22. El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663. doi:10.1002/14651858.CD006663.pub3
23. Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16. doi:10.1056/NEJM200107053450102
24. Engelen MA, Brand E, Baumeister TB et al (2012) Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open. doi:10.1136/bmjopen-2012-000879
25. Eto Y, Ohashi T, Utsunomiya Y et al (2005) Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 28:575–583. doi:10.1007/s10545-005-0575-y
26. Fuller M, Meikle PJ, Hopwood JJ (2006) Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Source Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford
27. Gadola SD, Silk JD, Jeans A et al (2006) Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med 203:2293–2303. doi:10.1084/jem.20060921
28. Garman RD, Munroe K, Richards SM (2004) Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin Exp Immunol 137:496–502. doi:10.1111/j.1365-2249.2004.02567.x
29. Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547–1557. doi:10.1681/ASN.2006080816
30. Gumperz JE, Miyake S, Yamamura T, Brenner MB (2002) Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 195:625–636
31. Hunn MK, Hermans IF (2013) Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. Oncoimmunology 2:e23789. doi:10.4161/onci.23789
32. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995. doi:10.1038/ni1112
33. Jou I, Lee JH, Park SY et al (2006) Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am J Pathol 168:1619–1630. doi:10.2353/ajpath.2006.050924
34. Keating GM (2012) Agalsidase alfa: a review of its use in the management of Fabry disease. BioDrugs 26:335–354. doi:10.2165/11209690-000000000-00000
35. Kim JH, Kim HS, Kim HY et al (2012) Direct engagement of TLR4 in invariant NKT cells regulates immune diseases by differential IL-4 and IFN-g production in mice. PLoS One 7:e45348. doi:10.1371/journal.pone.0045348
36. Lee K, Jin X, Zhang K et al (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305–313. doi:10.1093/glycob/cwg034
37. Li B, Desai SA, MacCorkle-Chosnek RA et al (2002) A novel conditional Akt “survival switch” reversibly protects cells from apoptosis. Gene Ther 9:233–244. doi:10.1038/sj.gt.3301641
38. Lidove O, West ML, Pintos-Morell G et al (2010) Effects of enzyme replacement therapy in Fabry disease–a comprehensive review of the medical literature. Genet Med 12:668–679. doi:10.1097/GIM.0b013e3181f13b75
39. Liebau MC, Braun F, Höpker K et al (2013) Dysregulated autophagy contributes to podocyte damage in Fabry’s disease. PLoS One 8: e63506. doi:10.1371/journal.pone.0063506
40. Linthorst GE, Hollak CEM, Donker-Koopman WE et al (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589–1595. doi:10.1111/j.1523-1755.2004.00924.x
41. Linthorst GE, Bouwman MG, Wijburg FA et al (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47:217–222. doi:10.1136/jmg.2009.072116
42. Lukas J, Giese A-K, Markoff A et al (2013) Functional character-isation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet 9:e1003632. doi:10.1371/journal.pgen.1003632
43. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 328:453–459. doi:10.1056/NEJM199302183280701
44. Ma J, Chadban SJ, Zhao CY et al (2014) TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 9:e97985. doi:10.1371/journal.pone.0097985
45. MacDermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760
46. MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775
47. Macedo MF, Quinta R, Pereira CS, Sa Miranda MC (2012) Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model. Mol Genet Metab 106:83–91. doi:10.1016/j.ymgme.2012.02.014
48. Mehta A, Beck M, Eyskens F et al (2010) Fabry disease: a review of current management strategies. QJM 103:641–659. doi:10.1093/qjmed/hcq117
49. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. J Am Med Assoc 281:249–254
50. Nakao S, Kodama C, Takenaka T et al (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 64:801–807. doi:10.1046/j.1523-1755.2003.00160.x
51. Namdar M, Gebhard C, Studiger R et al (2012) Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease. PLoS One 7:e36373. doi:10.1371/journal.pone.0036373
52. O’Reilly V, Zeng SG, Bricard G et al (2011) Distinct and overlapping effector functions of expanded human CD4+, CD8∝ + and CD4-CD8∝-invariant natural killer T cells. PLoS One 6:e28648. doi:10.1371/journal.pone.0028648
53. Ohashi T, Iizuka S, Ida H, Eto Y (2008) Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 94:313–318. doi:10.1016/j. ymgme.2008.03.008
54. Paduraru C, Bezbradica JS, Kunte A et al (2013) Role for lysosomal phospholipase A2 in iNKT cell-mediated CD1d recognition. Proc Natl Acad Sci U S A 110:5097–5102. doi:10.1073/pnas.1302923110
55. Pereira CS, Azevedo O, Maia ML et al (2013) Invariant natural killer T cells are phenotypically and functionally altered in Fabry disease. Mol Genet Metab 108:241–248. doi:10.1016/j. ymgme.2013.01.018
56. Prabakaran T, Nielsen R, Larsen JV et al (2011) Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease. PLoS One. doi:10.1371/journal.pone.0025065
57. Qian Y, Feldman E, Pennathur S et al (2008) From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57:1439–1445. doi:10.2337/db08-0061
58. Ramaswami U, Parini R, Pintos-Morell G et al (2012) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 81:485–490. doi:10.1111/j.1399-0004.2011.01671.x
59. Rolfs A, Böttcher T, Zschiesche M et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794–1796. doi:10.1016/S0140-6736(05)67635-0
60. Rombach SM, Dekker N, Bouwman MG et al (2010a) Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802:741–748. doi:10.1016/j.bbadis.2010.05.003
61. Rombach SM, Twickler TB, Aerts JMFG et al (2010b) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab 99:99–108. doi:10.1016/j. ymgme.2009.10.004
62. Rombach SM, Aerts JMFG, Poorthuis BJHM et al (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 7:e47805. doi:10.1371/journal. pone.0047805
63. Rombach SM, Smid BE, Bouwman MG et al (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47. doi:10.1186/1750-1172-8-47
64. Rombach SM, Smid BE, Linthorst GE et al (2014) Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. doi:10.1007/s10545-014-9677-8
65. Rozenfeld P, Agriello E, De Francesco N et al (2009) Leukocyte perturbation associated with Fabry disease. J Inherit Metab Dis 32(Suppl 1):S67–S77. doi:10.1007/s10545-009-1060-9
66. Sanchez-Niño MD, Sanz AB, Carrasco S et al (2011) Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 26:1797–1802. doi:10.1093/ndt/gfq306
67. Schellekens H (2008) The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. Clin Ther 30(Suppl B):S50–S51
68. Schiffmann R, Murray GJ, Treco D et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97:365–370
69. Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. J Am Med Assoc 285:2743–2749
70. Schiffmann R, Floeter MK, Dambrosia JM et al (2003) Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28:703–710. doi:10.1002/mus.10497
71. Schiffmann R, Ries M, Timmons M et al (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354. doi:10.1093/ndt/gfi152
72. Schiffmann R, Waldek S, Benigni A, Auray-Blais C (2010) Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol 5:360–364. doi:10.2215/CJN.06090809
73. Seki E, De Minicis S, Osterreicher CH et al (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13:1324–1332. doi:10.1038/nm1663
74. Shen J-S, Meng X-L, Moore DF et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95:163–168. doi:10.1016/j.ymgme.2008.06.016
75. Shu L, Vivekanandan-Giri A, Pennathur S et al (2014) Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease. Kidney Int. doi:10.1038/ki.2013.520
76. Sirrs SM, Bichet DG, Casey R et al (2014) Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 111:499–506. doi:10.1016/j.ymgme.2014.01.014
77. Smid BE, Hoogendijk SL, Wijburg FA et al (2013) A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab 108:132–137. doi:10.1016/j. ymgme.2012.12.005
78. Spada FM, Koezuka Y, Porcelli SA (1998) CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188:1529–1534
79. Spada M, Pagliardini S, Yasuda M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40. doi:10.1086/504601
80. Sugita M, Cernadas M, Brenner MB (2004) New insights into pathways for CD1-mediated antigen presentation. Curr Opin Immunol 16:90–95
81. Tanaka A, Takeda T, Hoshina T et al (2010) Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis 33(Suppl 3):S249–S252. doi:10.1007/s10545-010-9136-0
82. The STABILITY Investigators (2014) Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. doi:10.1056/NEJMoa1315878
83. Thomaidis T, Relle M, Golbas M et al (2009) Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney Int 75:399–407. doi:10.1038/ki.2008.576
84. Thomas AS, Mehta AB (2013) Difficulties and barriers in diagnosing Fabry disease: what can be learnt from the literature? Expert Opin Med Diagn 7:589–599. doi:10.1517/17530059.2013.846322
85. Tondel C, Bostad L, Larsen KK (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24(1):137–148. doi:10.1681/ASN.2012030316
86. Vedder AC, Linthorst GE, van Breemen MJ et al (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78. doi:10.1007/s10545-006-0484-8
87. Vedder AC, Breunig F, Donker-Koopman WE et al (2008) Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 94:319–325. doi:10.1016/j.ymgme.2008.03.003
88. Waldek S, Patel MR, Banikazemi M et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med 11:790–796. doi:10.1097/GIM.0b013e3181bb05bb
89. Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34–45
90. Wei H, Kim S-J, Zhang Z et al (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet 17:469–477. doi:10.1093/hmg/ddm324
91. Weidemann F, Niemann M, Störk S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331–341. doi:10.1111/joim.12077
92. West M, Nicholls K, Mehta A et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132–1139. doi:10.1681/ASN.2008080870
93. Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74
94. Wilcox WR, Linthorst GE, Germain DP et al (2012) Anti-∝-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab 105:443–449. doi:10.1016/j.ymgme.2011.12.006
95. Winchester B, Young E (2006) Biochemical and genetic diagnosis of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds) Source Fabry disease: perspectives from 5 years of FOS. Oxford PharmaGenesis, Oxford